Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development

Executive Summary

FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.
Advertisement

Related Content

Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint
Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends All-Cause Mortality As Sole Primary Endpoint
Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets
Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline
FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
Antibiotic Development Incentive Menu: Options Getting Longer
Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
Theravance Could Face Prospect Of Another Trial For Vibativ In HAP

Topics

Advertisement
UsernamePublicRestriction

Register

PS052697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel